A common metabolic pathway for several prostaglandins (PG), including PGE₂, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.¹ 13,14-dihydro-15-keto tetranor PGE₂ is a potential metabolite of PGE₂. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE₂ (Item No. 14650), which is known to have a short plasma half-life.^2,3,4

≥95%